Latest News

The Genital Psoriasis Wellness Consortium reached consensus on age-specific recommendations on screening, care, and special populations.

Data suggest long-term extracorporeal photopheresis may reduce mortality risk in patients with chronic lung allograft dysfunction unresponsive to standard immunosuppression.

May 2026 saw substantial FDA decisions, major trial results, guideline updates, and more.

View the top 6 trials to watch ahead of a star-studded ADA 2026.

Phase 3 post hoc data linked lorundrostat to lower systolic blood pressure and albuminuria in patients with hypertension and CKD.

The FDA declined to approve Cingulate's once-daily ADHD therapy CTx-1301, citing CMC information requests with no clinical safety or efficacy concerns identified.

A clinician explains how sparsentan is changing treatment strategies for patients with FSGS.

Chung, MD, explains why sparsentan remains valuable in FSGS despite a negative eGFR endpoint.

A clinical forum discussed referral dynamics, access barriers, and patient health literacy challenges that shape biologic use in the real world.

FDA accepts the BLA for povetacicept in IgA nephropathy, supported by positive phase 3 RAINIER trial data.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover topline data from the TRIUMPH-1 trial of retatrutide for obesity management.

Bernstein discussed the evolving role of biomarkers in chronic spontaneous urticaria at EAC 2026.

In this Q&A, Tatiana V. Kudryashova, PhD, discusses new data presented at ATS 2026 that show silencing E2F2 suppresses hyperproliferation in PAH smooth muscle cells.

Pooled B-Well phase 3 data show bepirovirsen achieved a 19% functional cure rate in CHB vs 0% with standard of care alone.

The FDA has approved fast-acting inhaled insulin Afrezza for pediatric patients aged 6-18 years with T1D or T2D.

This episode covers the FDA’s recent approval of MannKind’s inhaled insulin Afrezza for patients aged 6-18 years with either T1D or T2D.

This episode covers Abbott’s Libre Duo and Libre Duo 10 Day systems, Eli Lilly’s retatrutide, and the recent Dexcom sensor theft.

Saroglitazar received FDA Priority Review for adults with PBC after phase 3 data showed improved biochemical response versus placebo.

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

Explore OX40/OX40L inhibition in atopic dermatitis: phase 3 amlitelimab efficacy, safety signals, and what upstream immune control could mean.

The approval indicates linaclotide for pediatric patients ≥ 2 years of age with functional constipation, expanding its previous use in patients ≥ 6 years of age.

These topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with moderate-to-severe atopic dermatitis.